COMMUNIQUÉS West-GlobeNewswire

Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
15/09/2026
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch [...]
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
15/09/2026
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission [...]
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
15/09/2026
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to [...]
VitalHub Announces Expansion of AI Capabilities with Launch of AI Scribe
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the launch of VitalHub AI Scribe, an ambient clinical intelligence (“ACI”) solution that [...]
Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery
15/09/2026
Limited-Edition Release Continues Distillery's Celebration of the Art of Blending Through Whiskey, Visual Art and Community BRECKENRIDGE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the [...]
Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026
15/09/2026
Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of the fastest-growing segments in molecular imaging BEDMINSTER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Satellos to Present at the 31st Annual Congress of the World Muscle Society
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today [...]
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
15/09/2026
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no [...]
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
15/09/2026
Enrollment advances into Cohort 2 of Phase 1 trial of RPT1G in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS) U.S. Food and Drug Administration accepts Investigational [...]
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
15/09/2026
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a [...]
PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
15/09/2026
● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio ® , a late-stage biotechnology company addressing unmet needs in wound healing through innovation in [...]
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
15/09/2026
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage [...]
Ontario Healthcare Stakeholders Unite on Shared Action Plan to Reduce Tobacco and Nicotine Dependence
15/09/2026
Vanguard healthcare, policy, and community stakeholders consolidate as newly formed Ontario Nicotine Action Table (ONAT) to build long-term plan for coordinated action TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- A broad [...]
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that [...]
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
15/09/2026
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a [...]
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
15/09/2026
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies
15/09/2026
Eleva Biologics will seek strategic partnerships for development and manufacturing of first-in-class and previously inaccessible biologics discovered with the Bryotechnology platform One04 Therapeutics will focus on [...]
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
15/09/2026
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after [...]
C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
15/09/2026
A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company [...]

Pages